Aims:
The storm-like nature of the
health crises caused by COVID-19 has led to unconventional clinical
trial practices such as the relaxation of exclusion criteria. The
question remains: how can we conduct diverse trials without exposing
sub-groups of populations to potentially higher drug exposure levels?
The aim of this study was to build an extensive knowledge-base of the
effect of intrinsic and extrinsic factors on the disposition of several
repurposed COVID-19 drugs.